Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modeling

Moore, Julia A; Chow, James C. L.

doi:10.1088/2632-959x/abddd3

Cited by 82 publications

(51 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The particle size of these PFH/PLGA NPs is a nanometer, making it easier to accumulate in the tumor. 10,[15][16][17] To achieve precise HIFU ablation, the boundaries between tumor and normal tissue should be distinguished. However, most synergistic agents are stymied by non-specific organ biodistribution.…”

Section: Introductionmentioning

confidence: 99%

Bifidobacterium bifidum-Mediated Specific Delivery of Nanoparticles for Tumor Therapy

Tang¹,

Chen²,

Jiang³

et al. 2021

IJN

View full text Add to dashboard Cite

Purpose: Hypoxia is considered to be obstructive to tumor treatment, but the reduced oxygen surroundings provide a suitable habitat for Bifidobacterium bifidum (BF) to colonize. The anaerobe BF selectively colonizes into tumors following systemic injection due to its preference for the hypoxia in the tumor cores. Therefore, BF may be a potential targeting agent which could be used effectively in tumor treatment. We aimed to determine whether a novel BF-mediated strategy, that was designed to deliver AP-PFH/PLGA NPs (aptamers CCFM641-5-functionalized Perfluorohexane (PFH) loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles) by aptamer-directed approach into solid tumor based on the tumortargeting ability of BF, could improve efficiency of high intensity focused ultrasound (HIFU) treatment of breast cancer. Methods: We synthesized AP-PFH/PLGA NPs using double emulsion method and carbodiimide method. Then, we evaluated targeting ability of AP-PFH/PLGA NPs to BF in vivo. Finally, we studied the efficacy of HIFU ablation based on BF plus AP-PFH/PLGA NPs (BFmediated HIFU ablation) in tumor. Results: The elaborately designed AP-PFH/PLGA NPs can target BF colonized in tumor to achieve high tumor accumulation, which can significantly enhance HIFU therapeutic efficiency. We also found that, compared with traditional chemotherapy, this therapy not only inhibits tumor growth, but also significantly prolongs the survival time of mice. More importantly, this treatment strategy has no obvious side effects. Conclusion:We successfully established a novel therapy method, BF-mediated HIFU ablation, which provides an excellent platform for highly efficient and non-invasive therapy of tumor.

show abstract

Section: Introductionmentioning

confidence: 99%

Bifidobacterium bifidum-Mediated Specific Delivery of Nanoparticles for Tumor Therapy

Tang¹,

Chen²,

Jiang³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…With the advancement in nanotechnological approaches, it has now become possible to integrate a large number of components with various customized targeting strategies, therapeutic agents, and controlled-release mechanisms within an architecture framed at nano-scale [5]. The superiority of nanoparticles (NPs) in overcoming the multi-layered stromal-cell barriers for deeper tumor infiltration and drug perfusion makes it a promising future strategy for clinical applications either as an anticancer agent carrier or contrast agents in the biomedical imaging [6][7][8]. The current review symbolizes information about types and the occurrence of breast cancer (BC), a shift in the treatment paradigm from conventional to nanotechnological approaches for target specific delivery of therapeutic entities, along with mechanistic insights on the nanoparticle-induced endoplasmic reticulum unfolded protein response (UPR ER ) to overcome the resistance, and as such the progression of cancer cells towards gaining an insight into the development of novel therapeutics for employment in the treatment of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPRER) and Beyond

Rahman

Kumar

et al. 2021

Biomedicines

View full text Add to dashboard Cite

Breast cancer (BC) is the second most frequent cause of death among women. Representing a complex and heterogeneous type of cancer, its occurrence is attributed by both genetic (gene mutations, e.g., BRCA1, BRCA2) and non-genetic (race, ethnicity, etc.) risk factors. The effectiveness of available treatment regimens (small molecules, cytotoxic agents, and inhibitors) decreased due to their poor penetration across biological barriers, limited targeting, and rapid body clearance along with their effect on normal resident cells of bone marrow, gastrointestinal tract, and hair follicles. This significantly reduced their clinical outcomes, which led to an unprecedented increase in the number of cases worldwide. Nanomedicine, a nano-formulation of therapeutics, emerged as a versatile delivering module for employment in achieving the effective and target specific delivery of pharmaceutical payloads. Adoption of nanotechnological approaches in delivering therapeutic molecules to target cells ensures not only reduced immune response and toxicity, but increases the stability of therapeutic entities in the systemic circulation that averts their degradation and as such increased extravasations and accumulation via enhanced permeation and the retention (EPR) effect in target tissues. Additionally, nanoparticle (NP)-induced ER stress, which enhances apoptosis and autophagy, has been utilized as a combative strategy in the treatment of cancerous cells. As nanoparticles-based avenues have been capitalized to achieve better efficacy of the new genera of therapeutics with enhanced specificity and safety, the present study is aimed at providing the fundamentals of BC, nanotechnological modules (organic, inorganic, and hybrid) employed in delivering different therapeutic molecules, and mechanistic insights of nano-ER stress induced apoptosis and autophagy with a perspective of exploring this avenue for use in the nano-toxicological studies. Furthermore, the current scenario of USA FDA approved nano-formulations and the future perspective of nanotechnological based interventions to overcome the existing challenges are also discussed.

show abstract

“…24,25 Especially in the field of cancer therapy, nanomaterials have been extensively used to achieve effective and precise treatment. 26,27 For cancer immunotherapy, in contrast to subunit vaccines, nanovaccines have many practical advantages. Nanovaccines can be designed with diverse features, such as effective penetration through the tissue barriers, high cellular uptake in antigen-presenting cells (APCs), reliable protection and efficient delivery for antigens, also tunable antigen release and effective crosspresentation, and so on.…”

Section: Introductionmentioning

confidence: 99%

CpG-Based Nanovaccines for Cancer Immunotherapy

Chen¹,

Jiang²,

Yu³

et al. 2021

IJN

View full text Add to dashboard Cite

Cancer has been a serious health hazard to the people all over the world with its high incidence and horrible mortality. In recent years, tumor vaccines in immunotherapy have become a hotspot in cancer therapy due to their many practical advantages and good therapeutic potentials. Among the various vaccines, nanovaccine utilized nanoparticles (NPs) as the carrier and/or adjuvant has presented significant therapeutic effect in cancer treatment. For tumor nanovaccines, unmethylated cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN) is a commonly used adjuvant. It has been reported that CpG ODN was the most effective immune stimulant among the currently known adjuvants. It could be recognized by toll-like receptor 9 (TLR9) to activate humoral and cellular immunity for preventing or treating cancer. In this review, the topic of CpG-based nanovaccines for cancer immunotherapy will be focused. The types and properties of different CpG will be introduced in detail first, and then some representative tumor nanovaccines will be reviewed according to the diverse loading modes of CpG, such as electrostatic adsorption, covalent bonding, hydrophilic and hydrophobic interaction, and DNA self-assembly, for summarizing the current progress of CpG-based tumor nanovaccines. Finally, the challenges and future perspectives will be discussed. It is hoped that this review will provide valuable references for the development of nanovaccines in cancer immunotherapy.

show abstract

Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modeling

Cited by 82 publications

References 102 publications

Bifidobacterium bifidum-Mediated Specific Delivery of Nanoparticles for Tumor Therapy

Bifidobacterium bifidum-Mediated Specific Delivery of Nanoparticles for Tumor Therapy

Molecular Perspective of Nanoparticle Mediated Therapeutic Targeting in Breast Cancer: An Odyssey of Endoplasmic Reticulum Unfolded Protein Response (UPRER) and Beyond

CpG-Based Nanovaccines for Cancer Immunotherapy

Contact Info

Product

Resources

About